
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 05, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg".
Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 05, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg".
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals